Edinburgh, United Kingdom
Lentitek, founded in 2019 and headquartered in the United Kingdom, operates at the intersection of Biotechnology and Health Care. Their mission is captured by their slogan: "Enabling the next generation of medicines."
The company addresses a critical bottleneck within the field of gene and gene-modified cell therapies, such as CAR-T, focusing on significantly improving the production yield of viral vectors. By enhancing viral yield by over tenfold, Lentitek aims to lower production costs, thereby facilitating broader access to transformative therapies for patients in need.
Lately, Lentitek secured a £250.00K Seed Round investment on 30 May 2023, with contributions from Apollo Informal Investments, Gabriel Investments, Gillian MacAulay, and the University of Edinburgh. This financial backing represents confidence from a strong array of investors, supporting Lentitek's potential to revolutionize the biopharma production landscape.
